Alexandria Real Estate Equities owns lab and office buildings used by life science companies, but empty space is rising and the company just cut its payout to save cash. The flip side is that the shares trade at a steep discount to what its properties and projects could be worth if leasing and asset sales start to stabilize.Read more
Alexandria Real Estate Equities is betting that demand for high-end lab space in major research hubs keeps rising as drug and biotech work ramps up, helping it fill buildings and raise rents. But higher borrowing costs, slower tenant decisions, and new lab supply in key cities could make that growth bumpier than it looks.Read more
Key Takeaways Premium assets in major innovation clusters secure long-term leases with top tenants, supporting stable cash flows and above-market rent growth. Rising demand for specialized lab space and high entry barriers strengthen Alexandria's competitive position and earnings potential.Read more
Key Takeaways Rising costs, regulatory pressures, and shifts in workplace demand are squeezing margins and threatening predictability of earnings and occupancy rates. Heavy dependence on key biotech hubs and evolving funding trends increases revenue volatility and prolongs vacancy risks.Read more
Alexandria Real Estate Equities, Inc., an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator and developer of collaborative Megacampus ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City. Alexandria Real Estate Equities, Inc. is based in Pasadena, California and is established in January 05, 1994, and incorporated in Maryland.
